Cervical Cancer News & Features

Should informed consent mean the patient understands?

January 30, 2012

The patient understood that surgery was the best next step in her treatment. Or, did she?
 

Not Enough Americans Being Screened for Cancer

January 26, 2012

Rates of cancer screening in the United States are short of Healthy People 2020 targets for breast, cervical, and colorectal cancer screening
 

Self-testing for HPV may increase screening rates

Delicia Honen Yard November 17, 2011

Vaginal self-sampling for human papillomavirus testing demonstrated a relatively low but acceptable positive predictive value in a large trial of women in underserved areas of Mexico.
 

Oxygen generators help kill tumors from within

October 18, 2011

An electronic device that can be implanted in a tumor uses the energy from ultrasound signals to generate oxygen, boosting the effectiveness of radiation and chemotherapy.
 

HPV vaccine may work in fewer than three doses

Delicia Honen Yard September 29, 2011

The Cervarix vaccine for HPV may work with just one or two doses, rather than the standard three, according to an analysis of data from an National Cancer Institute (NCI)-sponsored trial.
 

Persistent HPV infection predicts cervical cancer risk

Delicia Honen Yard September 27, 2011

A large, long-term study indicates that women older than 30 years who test positive for human papillomavirus should be retested every 2 years to monitor cervical cancer risk.
 

Cervical abnormality rates fall in Australian girls after HPV vaccination

Delicia Honen Yard July 05, 2011

Following the introduction of a human papillomavirus vaccination program, high-grade cervical abnormalities fell by nearly half in girls aged 17 years and younger in Victoria, Australia.
 

Basic steps are best bet for detecting gynecologic cancer recurrence

Delicia Honen Yard June 17, 2011

The best approach for detecting most gynecologic cancer recurrences is to take a thorough history, perform a thorough examination, and educate the patient about concerning symptoms.
 

Dactinomycin trumps methotrexate for GTN

June 01, 2011

One dose of dactinomycin every 2 weeks results in a higher complete response rate than a weekly dose of methotrexate, the more commonly used drug.
 

Cancer prevention report highlights improvements, gaps

Delicia Honen Yard May 27, 2011

Smoking rates among US adults and youths have stalled over the past several years, but the increase in obesity appears to have slowed in the past decade.
 

Cervical Cancer Clinical Trials

Clinical Trial: Distribution of Human Papillomavirus (HPV) Genotypes in Patients With Cervical Cancer From Croatia (HPV-cancer)

Clinical Trial: Radical Trachelectomy for Cervical Cancer

Clinical Trial: Addressing Stigma in Screening and Diagnostic Delay for Cervical Cancer

Clinical Trial: Simple Versus Radical Hysterectomy for Stage I Cervical Cancer

Clinical Trial: Studying Biomarkers in Blood Samples From Patients With Invasive Cervical Cancer

Free CE from mycme.com

Discussions on Emerging Concepts and Controversies in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

2.00 / AMA PRA Category 1 Credit(s)TM
This program reviews developments in maintenance therapy and evaluates the relevance of tumor histology and biomarker analysis for the management of NSCLC patients.
 

Cancer care is expensive.
CancerCare can help.


Connect Booklets
ONA Newsletters
Sign up today for one of our free newsletters:
  • Issue Preview
  • Latest CE
  • Reflections
  • Editor's choice
  • New on the Web
 Subscribe to the RSS for this page  [view all our RSS feeds here]

Web Exclusives

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions